To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Blackstone in $3.6bn pharma exit
Twenty months after investing $500m in dermatology company Stiefel, the 162-year-old US company has been sold to GlaxoSmithKline.
